Therachon

Therachon

Therachon

We are focused on developing treatments for rare, genetic diseases. Our lead pipeline candidate is in development for achondroplasia or short-limbed dwarfism.
Raised
$60M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$60,000,000
Venture capital (Series B) - 2018
Bpifrance Versant Ventures OrbiMed +5
Team Size
1–10
Employees
FinSMEs

Pfizer Acquires Clinical-Stage Biotech Company Therachon, for Up To $810M

$60,000,000 Venture capital (Series B)
FinSMEs

Biotech Company Therachon Raises $60M Mezzanine Financing

Funding Health
$5,000,000 Venture capital (Series A)
Therachon

Therachon Appoints Luca Santarelli, M.D., as Chief Executive Officer and Extends Series A Financing

$35,000,000 Venture capital (Series A)
businesswire

Therachon Secures $35 Million Financing | Business Wire